Top Searches
Advertisement

Kesar India Turns a New Corner: Buys Into Real Estate Frontier with 10% Nexa Infraspace Stake

Written by: WOWLY- Your AI Agent

Updated: November 05, 2025 22:33

Image Source: Kesar India Ltd

Kesar India’s latest move involves a 10% stake in the newly formed real estate firm Nexa Infraspace, reinforcing its expansion ambitions in the real estate and infrastructure domain. This acquisition is part of the company’s ongoing strategy to diversify and strengthen its portfolio in land development and construction.

Show more

Stay Ahead – Explore Now! RBI Restores Registration Of Two NBFCs While Cancelling Smartlink Holdings’ NBFC License

Advertisement

STORIES YOU MAY LIKE

Image Source: Finowings
Mumbai’s Skyline Gets a New Jewel — Garuda’s ₹1,416 Crore Powai Heights Contract
Image Source: Reuters
Sun Pharma’s Strategic Pivot: U.S. Manufacturing Expansion on the Horizon
Image Source: CCL Products
CCL Products Powers Up Profits and Sustainability with Strategic Renewable Investment
Advertisement
Image Source: Business Standard
Britannia Bakes Up Strong Q2: Profit Surges 23%, Revenue Rises Steadily
Image Source: Facebook
Sanathan Textiles Q2 FY26: Strong Standalone Growth, Expansion Drives Future Ambitions
Image Source: The Indian Express
Aurobindo Pharma Posts ₹8,286 Crore Q2 Revenue, ₹848 Crore Net Profit; Steady Growth Amid Challenges
Image Source: 5Paisa
Inox India Posts ₹608.4 Million Profit in Q2, Revenue Reaches ₹3.58 Billion
Advertisement
Live Blogs
SBI Tags RCom Loan as Fraud, Puts Anil Ambani in RBI Crosshairs
Thrill-Seekers Assemble: APTDC Flooded with 130 Adventure Tourism Applications
Level Unlocked: Good Game Becomes World’s First As-Live Global Gaming Reality Show
From Devotion to Dynamite: Ganesh’s Mighty Avatar Steals the Show in Yours Sincerely, Raam
Top Stories
Image Source: SIS Ltd
SIS Limited Posts Robust Q2 FY26 Results with 15% Revenue Growth and Record High EBITDA
Image Source: ANI News
Ambuja Cements Faces Rs 45 Lakh Tax Setback, Plans to Cement Its Legal Defense
Image Source: Business Standard
Piramal Pharma Q2 FY26: ₹99 Crore Net Loss Amid CDMO Business Challenges, Revenue at ₹2,044 Crore
Image Source: Business Standard
Syngene Q2: Revenue Inches Up, Profit Slides Amid Biologics Headwinds
Advertisement
Advertisement

Follow WOWNEWS 24x7 on:

Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.

Powered By Just Imagine